VERAXA Biotech AG (NASDAQ: VRXA) has appointed Dr. Christoph Erkel, a specialist in antibody therapeutics, as its chief scientific officer. The appointment comes as the company prepares to advance its proprietary BiTAC® technology and broader oncology pipeline into clinical development, according to a recent announcement.
Dr. Erkel will be responsible for driving the company’s lead BiTAC-TCE program, which uses a conditionally active, dual-targeting approach designed to selectively activate T cells against cancer cells while potentially limiting effects on healthy tissue. This precision strategy aims to reduce off-tumor toxicity, a common challenge in T cell-engaging therapies.
The program has received recent scientific advice from Germany’s Paul-Ehrlich-Institute, providing additional clarity around its proposed non-clinical development strategy. Furthermore, preclinical data presented at the AACR Annual Meeting demonstrated selective activity against cells expressing both target molecules, underscoring the platform’s potential.
Beyond BiTAC, VERAXA is developing bispecific antibody-drug conjugates (ADCs) and other engineered antibody therapies, positioning the company to pursue multiple approaches to next-generation cancer treatment. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research.
The appointment of Dr. Erkel is significant because it brings specialized expertise to a critical juncture. As VERAXA transitions from preclinical research to clinical-stage development, strong scientific leadership is essential to navigate regulatory pathways and optimize trial design. The recent guidance from the Paul-Ehrlich-Institute and the promising preclinical data suggest that the BiTAC platform is maturing, and Dr. Erkel’s experience in antibody therapeutics could help translate these findings into successful human trials.
For investors and the biotech industry, this move signals VERAXA’s commitment to advancing its pipeline and could enhance the company’s attractiveness as a partner or acquisition target. The broader field of T cell engagers is highly competitive, but conditionally active approaches like BiTAC may offer safety advantages that set them apart. If successful, VERAXA’s therapies could provide new options for patients with hard-to-treat cancers.
VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline into clinical development and beyond. For regular updates, visit www.VERAXA.com.
